OHSU

Clinical Program

The Blood-Brain Barrier (BBB) consists of a layer of endothelial cells that line the blood vasculature throughout the brain. This layer is held together by tight junctions that prevent small molecules from diffusing through the gaps between the cells, the so-called paracellular route. Because diffusion of molecules across the cells by other means, pinocytosis for example, is minimal, it is these tight junctions and their inherent impermeability to water soluble molecules, or molecules larger than 200-400 daltons, that creates the blood-brain barrier. Dr. Neuwelt's research paper "Mechanisms of Disease: The Blood Brain Barrier" (Neurosurgery, January, 2004) is available on request.

 

Vessels of human brain

 

 

 Blood vessels in human brain. A plastic emulsion was injected into brain vessels and brain parenchymal tissue was dissolved. (photo on left).

Zlokovic & Apuzzo: Neurosurgery 43(4):877-878, 1998. (provided by permission from Lippincott Williams & Wilkins)

 

Electron micrograph of blood-brain barrier

 

 

 

 

The electron micrograph (on the right) shows electron dense lanthanum (dark areas in vessel lumen) unable to penetrate beyond a tight junction (arrow) between endothelial cells (labeled E).
(provided courtesy Dr. Milton Brightman at the NIH)

 

 

Blood-Brain Barrier Opening

 

Permeability of the BBB

Permeability of the BBB after BBBD is shown by the electron micrograph of peroxidase staining (indicated by arrow) between endothelial cells (labeled E).
(provided courtesy Dr. Milton Brightman at the NIH)

 

 

 

Intracarotid or intravertebral infusion of hyper osmotic saccarides (e.g. mannitol) leads consistently to a reversible opening of the barrier. This successful and noninvasive way of introducing therapeutic agents in patients with brain tumors has the disadvantage of randomly disseminating potentially neurotoxic agents throughout the brain.

Although some studies have shown that the use of oral (Temodar) or intravenous (BCNU) adjuvant chemotherapy following surgery prolongs survival in a selected group of patients, these improvements have generally been modest, and the great majority of patients are not cured. Limited therapeutic success in the treatment of CNS neoplasia with chemotherapy is generally attributed to two factors: natural or acquired resistance to chemotherapy expressed by tumor cells, and delivery impediment related to the BBB. The goal of the BBBD procedure is to maximize the delivery of the chemotherapeutic agent to the tumor cells for a given systemically administered dose. This increase in delivery also serves the purpose of increasing the therapeutic index/toxicity ratio. It has been shown in preclinical animal studies that a marked increase in water-soluble agent concentration (10- to 100-fold) can be induced in the brain, tumor and CSF after osmotic BBBD and intra-arterial administration (Neuwelt 1998). Kraemer (2002), a statistician with the BBB program, has reviewed the importance of dose intensity in CNS tumor treatment.

While many chemotherapeutics exhibit excellent activity in vitro, their therapeutic efficacy is often significantly diminished when administered, since they are unable to gain access to the diseased sites at a sufficient concentration for an appropriate time. This problem is commonly encountered by neuro-oncologists in the treatment of both primary and metastasic brain tumors. The goal of intra-arterial infusion is to increase the therapeutic index of a compound that already demonstrates activity following its IV administration. The intra-arterial route is more advantageous than systemic (IV) drug administration (which includes direct IV, oral, intramuscular, subcutaneous, intraperitoneal and even inhalation whereby drug enters the venous system before reaching the brain) because of these factors:

  1. With intra-arterial infusion, the first circulation of the drug is through the brain. After the drug leaves the target and enters the systemic circulation its pharmacokinetics are similar to those following IV administration.
  2. With regards to the toxicity, numerous studies have clearly established this route, combined with osmotic disruption, is a safe and consistent treatment modality. Please see the Institute for Clinical Systems Improvement report on blood brain barrier disruption chemotherapy.
  3. An increase in concentration of the drug at the target site will result in an increase in activity if a maximal effect has not already been achieved (Kraemer 2002).

 

Drugs that are ideal for intra-arterial infusion must enter tumor cells and possess a short half-life. The hyperosmotic disruption technique is one of the most widely used methods to open the blood-brain-barrier. A 30 second continuous intra-arterial infusion of mannitol in a given circulation at a rate sufficient to fill the whole vascular tree of that circulation produces an osmotic gradient that draws free water from the endothelial cells and osmotically shrinks the cells. At present, in clinical assessment at multiple centers, its value in a variety of adult and pediatric brain tumors is being assessed. Additional techniques are based on different mechanisms and include bradykinin receptor-induced barrier permeability modification (RMP-7) as well as NO-induced changes in vasodilation of brain tumor capillaries.

Indications

Blood-Brain Barrier Disruption (BBBD) is currently used clinically to increase the delivery of chemotherapeutic agents and in some cases monoclonal antibodies (mAb) for the treatment of brain tumors. Any central nervous system neoplasm with infiltrating features, chemo sensitivity, and potential to spread cells to the cerebrospinal fluid (CSF) has the possibility of being treated with intra-arterial chemotherapy with blood-brain barrier disruption. Please review the currently open studies at clinical trials.

Contraindications

The blood-brain barrier disruption technique is a physiologically stressful procedure. It produces a transient rise in intra-cranial pressure (ICP) from normal baseline values of 3 to 9 cm H2O to peaks of 16-23 cm at 30 minutes post disruption. This transient rise in ICP has been shown to correlate with a 1.5 percent increase in brain fluid content. In preclinical studies, this transient increase in ICP was not associated with any clinical sequelae (Neuwelt 1989). It illustrates, however, the rationale behind the very first contraindication of osmotic BBBD: the presence of significant mass effect.

Therefore, the following criteria must be used:

  • Patients with radiological signs of intra-cranial herniation with associated rapid neurologic deterioration are ineligible. 

 All other patients displaying significant radiological signs of mass effect, but not strictly adhering to these two absolute contraindications, must be individually and carefully screened. In general, patients with significant mass effect will initially undergo intra-arterial chemotherapy infusion without BBBD until decrease in tumor bulk safely allows a disruption.

Other contraindications include:

  • Patients with evidence of spinal cord block from tumor mass
  • Patients who have an Eastern Cooperative Oncology Group (ECOG) performance score equal to or greater than 3
  • Patients who are not expected to survive for more than 3 months from initiation of treatment
  • Patients at significant increased risk for general anesthesia
  • Patients who are pregnant

Clinical Studies Open to Subject Enrollment

Following is information regarding clinical studies that are approved by the OHSU Cancer Institute and the OHSU Institutional Review Board, and that are open to subject enrollment. Our recent translational laboratory and clinical studies focus on three areas:

  • Clinical studies of newly diagnosed primary central nervous system lymphoma
  • Clinical studies of anaplastic oligodendroglioma or oligoastrocytoma
  • Pre-clinical and clinical studies of chemoprotective agents to provide bone marrow and hearing protection for subjects with malignant brain tumors undergoing alkylating chemotherapy
  • Pre-clinical and clinical studies of new agents for MR imaging of malignant brain tumors, multiple sclerosis and stroke

Clinical Studies for Subjects with Primary Central Nervous System Lymphoma

For subjects with newly diagnosed primary central nervous system lymphoma (PCNSL), we offer a protocol utilizing a monoclonal antibody (rituximab) administered i.v. the day before carboplatin and methotrexate-based chemotherapy administered in conjunction with blood-brain barrier disruption. In addition, delayed sodium thiosulfate is administered i.v. for hearing protection. This is a multi-center protocol developed by our program at OHSU and open at several centers participating in the Blood-Brain Barrier Disruption Consortium. Eligible subjects must be within 90 days of PCNSL diagnosis, and must not have undergone prior radiation.

Clinical Studies for Subjects with Anaplastic Oligodendroglioma or Oligoastrocytoma

For subjects withanaplastic oligodendroglioma or oligoastrocytoma, we offer a phase I/II protocol to evaluate the combination of carboplatin, melphalan and etoposide phosphate administered in conjunction with blood-brain barrier disruption. Eligible subjects must have had prior temozolomide. If the subject has not received prior radiation, then a radiation consult must be obtained prior to study entry. This is a multi-center protocol developed by our program at OHSU and open at some of the centers participating in the Blood-Brain Barrier Disruption Consortium.

 

Clinical Studies using Chemoprotectants for Bone Marrow and Hearing Protection, in Subjects with Malignant Brain Tumors


CONFLICT OF INTEREST: Dr. Neuwelt, OHSU, Portland Veterans Affairs Medical Center (PVAMC) and the Department of Veterans Affairs have a significant financial interest in one of the experimental treatments used in this study that could result in financial benefit if the study is successful. This potential conflict of interest was reviewed and managed by the OHSU Integrity Program Oversight Council and the PVAMC Conflict of Interest in Research committee. If you would like more information, you may contact the OHSU Research Integrity Office at (503) 494-7887. Dr. Neuwelt has divested all financial interest in Adherex.

A current area of study by our program is the use of thiols as chemoprotectants. We have studied sodium thiosulfate since 1995 as a potential protectant against carboplatin-based hearing loss. The hearing protection studies are funded by a Veterans Administration Merit Review Grant. The clinical results were published in Clinical Cancer Research (7:493-500, 2001). Additionally, a recent review of subjects with malignant brain tumors treated with carboplatin with or without delayed sodium thiosulfate, showed that subjects who received thiosulfate required significantly fewer platelet transfusions and dose reductions of chemotherapy.

For subjects with high-grade glioma, we offer a phase II clinical study based on the above preliminary chemoprotection results. This study involves treatment with intra-arterial carboplatin-based chemotherapy (without blood-brain barrier disruption). Subjects are randomized to treatment with or without delayed sodium thiosulfate as a potential protectant against severe thrombocytopenia. This is a multi-center study which is open to enrollment at OHSU and at several additional centers.

 

Clinical Studies using New Neuro-Imaging Agents

A new area under study by our laboratory and clinical teams is the use of iron oxide contrast agents for MR imaging of malignant brain tumors and the evaluation of the impact of field strength (3T versus 7T). We also use contrast agents containing iron for imaging subjects with other neurologic disorders such as stroke and multiple sclerosis. When using iron oxide contrast agents for imaging different neurological diseases, we are seeing enhancing lesions not seen with commonly used MR contrast agents such as Gadolinium. Inflammation plays an important role in the pathogenesis of stroke, multiple sclerosis and radiation injury. Iron oxide contrast agents are known to be a cell-specific MRI contrast agent taken up by macrophages. Therefore, we use these particles to monitor disease activity and efficacy of therapy.

Please see clinical trials for information and eligibility requirements for specific studies.